The microbial toxin colibactin has just the right shape to snuggle up to DNA — but its embrace is unfortunately more cancerous than cozy. Colibactin is produced by bacteria in the gut and causes ...

As scientists question the rise in early colon cancer cases, a new study is offering some potential answers. Colored scanning electron micrograph (SEM) of a macrophage white blood cell (center) that ...

Health insurance companies send all kinds of things in the mail: brochures about benefits, branded items such as coasters and duffel bags, and reminders to get certain health tests done. Some have ...

We run for so many reasons, but a main one: It’s simply good for us. Running, and exercise in general, has been shown in study after study to protect against all kinds of chronic disease, including ...

A Chicago establishment described as "so much more than a bookstore" was named among America's "nicest" places by a nationwide magazine. Reader's Digest unveiled the five winners of its "Nicest Places ...

Every year, doctors diagnose more than 107,000 cases of colorectal cancer. While survival rates have improved, it's still the second-leading cause of cancer deaths in men and women combined. Knowing ...

Emilio Colon remembers his first meeting with Kevin Bradley back in the summer of 1989, like it was yesterday. “I was on the practice field at Lawrence High playing catch. I was a receiver/defensive ...

A new study looks into how cruciferous vegetables like broccoli and cauliflower may lower colon cancer risk. Daily consumption of the vegetable type could lower risk by 20%, according to the findings.

Extreme runners may have a higher risk of precancerous colon lesions, according to a study that's recently drawn attention thanks to social media chatter and a New York Times article. At the recent ...

A small, preliminary study found that marathoners were much more likely to have precancerous growths. Experts aren’t sure why. A study of 100 marathon and ultramarathon runners aged 35 to 50 found ...

The results of the phase 3 ATOMIC trial fired another volley in the ongoing debate over adjuvant vs neoadjuvant immunotherapy for patients with locally advanced colon cancer. But experts are divided ...